Tesamorelin vs Ipamorelin: Key Differences
Tesamorelin and ipamorelin are both used to raise growth hormone, but they work through different receptors and suit different research goals. This comparison lays out the key differences. Research information only.
Different mechanisms, same goal
Tesamorelin is a GHRH analog. It mimics the natural signal that tells the pituitary to release growth hormone. Ipamorelin is a ghrelin mimetic, also called a growth hormone secretagogue, that triggers release through the ghrelin receptor. Both increase growth hormone, but they push different buttons.
| Feature | Tesamorelin | Ipamorelin |
|---|---|---|
| Class | GHRH analog | Ghrelin mimetic |
| Receptor | GHRH receptor | Ghrelin receptor |
| Human data | Clinically approved use | Mostly research |
| Typical dose | 1 to 2 mg daily | 100 to 300 mcg per dose |
| Selectivity | Targeted GHRH action | Low cortisol / prolactin impact |
When each is studied
Tesamorelin has the stronger human record, driven by its approved use for reducing visceral fat, as explained in what does tesamorelin do. Ipamorelin is prized in research for being selective and clean, and it pairs well with a GHRH peptide like CJC-1295, as covered in the stack dosage guide.
Choosing a starting point
For dosing specifics see the tesamorelin dosage guide and the ipamorelin protocol. Whichever you study, accurate measurement and tested material are the constants.